- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05395507
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia
A Prospective, Multicenter, Randomized Controlled Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Adult Essential Thrombocythemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, open-label, multicenter, randomized controlled clinical trial between Interferon Alfa and Pegylated Interferon Alfa-2b in adult essential thrombocythemia (≥18 years).
Patients will be randomly divided into the following two treatment groups: 1. Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available. 2. Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
The dosage will be adjusted according to the results of laboratory examinations and patient tolerance. The patient will be transferred to the other group if intolerance or resistance occurs.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lei Zhang, MD
- Phone Number: 8602223909240
- Email: zhanglei1@ihcams.ac.cn
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Recruiting
- Institute of Hematology & Blood Diseases Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥18 years old.
- Male or Female.
- Diagnosis of essential thrombocythemia according to the 2016 World Health Organization criteria.
- Those who have not use interferon within 4 weeks before the first medication.
- Patients with indications for cytoreductive therapy.
- Men and women with reproductive potential, as well as all women with menopause less than 2 years, must agree to use acceptable contraceptive methods until 28 days after the last dose of study drug, and women must agree not to breastfeed during the study period.
- Voluntary written informed consent.
Exclusion Criteria:
- Resistance, or intolerance, or any contraindications to interferon.
- Patients with active thrombosis or active bleeding.
- Neutrophil count < 1.0x10^9/L.
- Hemoglobin < 11g/dL for male, or < 10g/dL for female.
- Poor control of thyroid dysfunction.
- Patients with a prior malignancy within the last 3 years.
- Patients with severe cardiac or pulmonary dysfunction.
- Severe renal damage (creatinine clearance < 30 ml / min).
- Severe liver dysfunction (ALT or AST > 2.5×ULN).
- Patients with hepatitis B virus, hepatitis C virus replication or HIV infection.
- Patients with a history of drug / alcohol abuse (within 2 years before the study).
- Patients that have participated in other experimental researches within one month before enrollment.
- History of psychiatric disorder.
- Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Recombinant Interferon Alpha
Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week.
Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
|
Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week.
Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
|
Experimental: Pegylated Interferon Alfa-2b
Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
|
Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete hematological remission (CHR) rates
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52
|
The CHR rates defined as European Leukemia Net will be compared between the two groups.
|
From the start of study treatment (Week 0) up to the end of Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CHR rates at week 24 and 36
Time Frame: From the start of study treatment (Week 0) up to the end of Week 24 and Week 36, respectively
|
The CHR rates at week 24 and 36 will be compared between the two groups
|
From the start of study treatment (Week 0) up to the end of Week 24 and Week 36, respectively
|
Time to CHR
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
The time of reaching CHR will be compared between the two groups
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
The proportion of patients crossed to the contralateral group
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
The proportion of patients crossed to the contralateral group will be compared between the two groups
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
The CHR rates after crossover
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
The CHR rates within 52 weeks after crossover
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Impact of therapy on driver mutations
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
To compare the proportion of subjects that display change on key biomarkers of the disease- JAK2V617F, CALR, MPL mutations.
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Impact of therapy on non-driver mutations
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
To compare the proportion of subjects that display change on key non-driver biomarkers of the disease-DNMT3A, ASXL1, TET2 or other mutations.
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Change of splenomegaly
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
To compare the proportion of subject with improvement and no progress rate of splenomegaly between the two groups.
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Change of bone marrow pathology
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
To compare the rate of patients with improvement and no progress rate of bone marrow pathology between the two groups
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
The incidence of major thrombotic events
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
To compare the incidence of major thrombotic events between the two groups.
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
The incidence of major bleeding events
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
To compare the incidence of major bleeding events between the two groups.
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
The incidence of progressing to bone marrow fibrosis
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
The incidence of progressing to bone marrow fibrosis will be compared between the two groups
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
The incidence of progressing to acute leukemia
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
The incidence of progressing to acute leukemia will be compared between the two groups
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Change in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
To compare the proportion of subjects that display change in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (0-100 scores, higher scores mean a worse outcome) between different treatment groups.
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Change of quality of life
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
Compare the rate of patients with improvement in quality of life between the two groups (assessed by EORTC quality of life scale QLQ-C30 V3.0 questionnaire).
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Change of microcirculation disturbance
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
The rate of patients with improvement in microcirculation disturbance (such as pruritus, headache, dizziness, chest tightness, erythematous limb pain and limb paresthesia) will be compared between the two groups
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Specific pre-defined toxicity
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
To compare incidence of specific pre-defined toxicity including fatigue, flu-like symptoms, dizziness, injection site necrosis, dyspnea, pain, depression, blurred Vision, insomnia, anorexia, weight Loss, weakness, pruritis, sweating, fever, decreased Libido, hot Flashes, flushing.
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of immune cell subgroups
Time Frame: From the start of study treatment (Week 0) up to the end of Week 52.
|
The proportion of T lymphocyte, B lymphocyte and dendritic cell subsets and the changes of gene expression profile of these cells will be analyzed before and after treatment.
|
From the start of study treatment (Week 0) up to the end of Week 52.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lei Zhang, MD, Institute of Hematology & Blood Diseases Hospital, China
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Thrombocytosis
- Thrombocythemia, Essential
- Thrombocytopenia
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Interferon alpha-2
- Peginterferon alfa-2b
Other Study ID Numbers
- Peg-IFNα-ET-2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Thrombocytopenia
-
Institute of Hematology & Blood Diseases Hospital...RecruitingEssential ThrombocytopeniaChina
-
Novartis PharmaceuticalsTerminatedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential ThrombocytopeniaUnited States
-
CTI BioPharmaTerminatedPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
-
Weill Medical College of Cornell UniversityColumbia University; New York Presbyterian HospitalCompletedAlloimmune Thrombocytopenia | Fetal Alloimmune ThrombocytopeniaUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sylvia ElzekUnknownThrombocytopenia Neonatal
-
Addpharma Inc.Completed
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
Clinical Trials on Recombinant Interferon Alpha
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Fudan UniversityUnknownHepatocellular CarcinomaChina
-
The Cleveland ClinicNational Cancer Institute (NCI)CompletedMelanoma | Sarcoma | Lymphoma | Kidney Cancer | Breast Cancer | Multiple Myeloma | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Anhui Medical UniversityFirst Affiliated Hospital Bengbu Medical College; The Second Hospital of Anhui... and other collaboratorsRecruiting
-
Institute of Hematology & Blood Diseases Hospital...RecruitingEssential ThrombocytopeniaChina
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBladder Cancer | Urethral CancerUnited States
-
Fudan UniversityWithdrawn
-
Lee's Pharmaceutical LimitedNot yet recruiting
-
Shanghai Jiao Tong University School of MedicineUnknown2019 Novel Coronavirus InfectionChina